MedTrace Logo

TAP vs. ESP Block for Gynecological Post Operative Pain

NCT06044779 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-09-22

No results posted yet for this study

Summary

The goal of this double blind randomized controlled trial is to compare transversus abdominis plane block and erector spinae plane block in gynecological surgery patients. The main questions it aims to answer are:

* What are the numerical post-operative pain scores in these two groups?
* Is there any significant difference in the numerical post-operative pain scores between subjects who underwent TAP block and subjects who underwent ESP block?
* What are the differences in the time needed for additional morphine in these two groups?
* Is there any significant differences in the time needed for additional morphine between subjects who underwent TAP block and subjects who underwent ESP block?

Conditions

  • Nerve Block
  • Pain, Postoperative

Interventions

PROCEDURE

Transversus Abdominis Plane Block using 0.25% Bupivacaine

TAP block regional anesthesia with ultrasound guidance with administration of 20 mL of 0.25% Bupivacaine in the abdominal wall before the operation is completed. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.

PROCEDURE

Erector Spinae Plane Block using 0.25% Bupivacaine

Regional anesthesia ESP block under ultrasound guidance with 20 mL of 0.25% bupivacaine at the tip of the transverse process at the T9 level before completion of surgery. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.

Sponsors & Collaborators

  • Universitas Padjadjaran

    lead OTHER

Principal Investigators

  • Doddy M Tavianto, MD · Faculty of Medicine Universitas Padjadjaran Bandung

  • Osmond M Pison, MD · Faculty of Medicine Universitas Padjadjaran Bandung

  • Azka P Rakhimulllah, MD · Faculty of Medicine Universitas Padjadjaran Bandung

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-27
Primary Completion
2023-03-26
Completion
2023-03-26

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06044779 on ClinicalTrials.gov